Last reviewed · How we verify
Camtobell (BELOTECAN)
At a glance
| Generic name | BELOTECAN |
|---|---|
| Sponsor | Chong Kun Dang |
| Drug class | belotecan |
| Target | DNA topoisomerase 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Malignant tumor of ovary
- Non-small cell lung cancer
Common side effects
Key clinical trials
- Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient (PHASE3)
- A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer (PHASE2)
- Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial (PHASE2)
- A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer (PHASE1,PHASE2)
- Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy (PHASE2)
- Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung Cancer (PHASE2)
- Safety Study of S-CKD602 in Patients With Advanced Malignancies (PHASE1)
- Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Camtobell CI brief — competitive landscape report
- Camtobell updates RSS · CI watch RSS
- Chong Kun Dang portfolio CI